U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE:ABBV) RINVOQ^® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

This approval is supported by efficacy and safety data from the Phase 3 SELECT-AXIS 2 clinical trial (Study 1) and the Phase 2/3 SELECT-AXIS 1 clinical trial evaluating RINVOQ.